Envarsus xr and Electrolyte imbalance - a phase IV clinical study of FDA data

Summary:

Electrolyte imbalance is reported as a side effect among people who take Envarsus xr (tacrolimus), especially for people who are female, 50-59 old, also take Simulect, and have Immune tolerance induction.

The phase IV clinical study analyzes which people have Electrolyte imbalance when taking Envarsus xr. It is created by eHealthMe based on reports of 3,807 people who have side effects when taking Envarsus xr from the FDA, and is updated regularly.

What is Envarsus xr?

Envarsus xr has active ingredients of tacrolimus. eHealthMe is studying from 3,819 Envarsus xr users. Check the latest studies of Envarsus xr.

What is Electrolyte imbalance?

Electrolyte imbalance is found to be associated with 1,091 drugs and 1,219 conditions by eHealthMe. Check the latest studies of Electrolyte imbalance.

On Jul, 11, 2026

3,807 people reported to have side effects when taking Envarsus xr.
Among them, 13 people (0.34%) have Electrolyte imbalance.

Could Envarsus xr cause Electrolyte imbalance?

Among these 13 people:

What is the gender of people who have Electrolyte imbalance when taking Envarsus xr? *

female: 100 %
male: 0.0 %

What is the age of people who have Electrolyte imbalance when taking Envarsus xr? *

What are other drugs people take besides Envarsus xr? *

Simulect: 12 people, 92.31%
Midazolam: 8 people, 61.54%
Piperacillin And Tazobactam: 6 people, 46.15%
Clopidogrel: 6 people, 46.15%
Ciclosporin: 5 people, 38.46%
Acetylsalicylic Acid: 3 people, 23.08%
Sulfamethoxazole And Trimethoprim: 2 people, 15.38%
Fluconazole: 1 person, 7.69%
Aspirin: 1 person, 7.69%
Ciprofloxacin: 1 person, 7.69%

What are other side effects people have besides Electrolyte imbalance? *

Pneumonia: 13 people, 100.00%
Immunosuppressant Drug Level Increased: 13 people, 100.00%
Cardiac Failure: 12 people, 92.31%
Cardiogenic Shock (inadequate circulation of blood): 12 people, 92.31%
Cardiac Arrest: 12 people, 92.31%
Haematoma (collection of blood outside the blood vessels): 12 people, 92.31%
Anaemia (lack of blood): 12 people, 92.31%
Acid Base Balance Abnormal: 11 people, 84.62%
Hypotension (abnormally low blood pressure): 11 people, 84.62%
Inflammation: 11 people, 84.62%

What are the existing conditions these people have? *

Immune Tolerance Induction: 10 people, 76.92%
Sedation: 8 people, 61.54%
Urinary Tract Infection: 5 people, 38.46%
Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 5 people, 38.46%
Cardiac Disorder: 4 people, 30.77%
C-Reactive Protein Increased: 4 people, 30.77%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 2 people, 15.38%
Sinus Tachycardia (a heart rhythm with elevated rate of impulses originating from the sinoatrial node): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Envarsus xr and have Electrolyte imbalance?

- Check whether Electrolyte imbalance is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Envarsus xr:

Envarsus xr (3,819 reports)

Browse all side effects of Envarsus xr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Electrolyte imbalance:

Electrolyte imbalance (1,091 drugs)

Browse all the conditions that are associated with Electrolyte imbalance:

Electrolyte imbalance (1,219 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Envarsus xr) and Envarsus xr (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.